OAKES FRANK R. 4
4 · Stellar Biotechnologies, Inc. · Filed Oct 12, 2018
Insider Transaction Report
Form 4
OAKES FRANK R.
DirectorPresident, CEO & Director
Transactions
- Sale
Common Shares, without par value
2018-10-12$1.31/sh−3,000$3,930→ 51,924 total
Footnotes (2)
- [F1]These shares were sold pursuant to a trading plan adopted by the reporting person in accordance with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended.
- [F2]The Issuer completed a 1-for-7 reverse share split of its common shares effective May 4, 2018. The amount stated reflects the post-split adjustment. Fractional shares resulting from the reverse share split were rounded to the nearest whole share.